| Treatments | No. of studies with adverse events* | Total randomized sample | No. of studies with adverse events at each time point | No. of studies with PCR-corrected ACPR** | No. studies/No. of patients with PCR corrected ACPR (total assessed) | ||||
| Day 28 | Day 42 | Total randomized participants with ACPR on Day 28 | Day 28 | Total randomized participants on Day 42 | Day 42 | ||||
| AQSP | 5 | 793 | 4 | 5 | 10 | 2623 | 10/1684 | 1/439 | |
| AL | 41 | 8979 | 38 | 12 | 63 | 13,435 | 63/11,546 | 20/3420 | |
| ASAQc | 5 | 1226 | 3 | 2 | 5 | 1441 | 3/1185 | 2/282 | |
| ASAQCPH | 1 | 54 | 1 | 1 | 1 | 54 | 1/47 | ||
| ASAQf | 10 | 2478 | 9 | 4 | 17 | 4225 | 17/3832 | 1085 | 6/856 |
| ASAQl | 9 | 929 | 8 | 1 | 22 | 2857 | 22/2407 | 238 | 2/199 |
| ASATPG | 1 | 100 | 1 | 0 | 1 | 70 | 1/60 | 0 | 0 |
| ASCD | 3 | 1505 | 2 | 0 | 3 | 677 | 1/521 | 359 | 1/302 |
| ASMQ | 3 | 552 | 2 | 1 | 5 | 683 | 5/646 | 302 | 2/204 |
| ASPY | 1 | 355 | 1 | 0 | 1 | 673 | 628 | 565 | 673 |
| ASSMP | 3 | 837 | 3 | 0 | 4 | 1087 | 4/1022 | ||
| ASSP | 2 | 750 | 2 | 0 | 14 | 1976 | 13/1790 | 135 | 1/112 |
| DHPP | 15 | 4938 | 14 | 7 | 24 | 6972 | 24/5655 | 2400 | 9/2111 |
| DHPPT | 1 | 212 | 1 | 0 | 1 | 212 | 204 | ||